Friday, July 10, 2026

pharma · Bleeding Complication During Colon Polypectomy · Cancer of Colon

Yang Xiaotian

Yang Xiaotian clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
5
Drugs
2
Patents
0
Intelligence · Clinical Programs

Yang Xiaotian projects

5 ClinicalTrials.gov programs sponsored by Yang Xiaotian.

Yang Xiaotian has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Ilaprazole

    Yang Xiaotian

    Erosive Esophagitis

    phase 3 small molecule completed

    1 trial
  2. Blood test

    Yang Xiaotian

    Cancer of Colon

    phase 2 other completed

    1 trial
  3. Ilaprazole

    Yang Xiaotian

    Gastric Cancer

    approved small molecule completed

    1 trial
  4. Aspirin

    Yang Xiaotian

    Bleeding Complication During Colon Polypectomy

    small molecule active

    1 trial
  5. sequential combined AVS

    Yang Xiaotian

    Primary Aldosteronism

    other active

    1 trial

Frequently asked questions

How many clinical projects does Yang Xiaotian have?

5 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.